What difference does telling patients explicitly that they are receiving placebos with no pharmacologically active ingredient have on their effect?
What specific feature in the neurobiology of fatigue make it most suited to the use of OLPs for management? Does the absence of a single receptor- peripheral lesion make it particularly suited to OLP use, from an etiologic point of view?
Amongst conditioning, therapeutic ritualization and enhanced clinician-patient interaction, which underlying mechanism is to be considered most central to the action of an OLP?
Is the neurobiology of an OLP specific to the patient population under study?
What features of an OLP make it most suited to the palliative philosophy – the lack of an element of deception, the reduction in pill burden, absence of toxicity?

It is usually acknowledged that fatigue arises as a result of multiple processes involving altered reward and motivation networks rather than a single dominant lesion signifying tissue dysfunction. This altered etiopathogenesis, which shares common origins with breathlessness, makes these symptoms most fertile for the use of OLPs.

Research has shown that OLPs have shown maximum benefit in conditions where expectation and symptom appraisal are expected to contribute most to symptom severity. Involvement of motivational networks and threat appraisal networks points towards symptom-specific expression and underlines the need for population-specific validation.

Interactions between a ritual with the ability to generate predictive signals with the potential to modify symptom perception (ritualization) and deepening of a therapeutic alliance in a setting where deception has been removed from the equation might be factors contributing towards its effect.

Though trials in Cancer-related fatigue are few, it is the data generated in the non-cancer population which lends itself to extrapolation. Research in the advanced cancer population remains limited.

The need to position OLPs as adjunctive treatment, and the avoidance of placing them before pharmacological treatment constitutes a valid practice point.

References

Kaptchuk, T. J., Friedlander, E., Kelley, J. M., Sanchez, M. N., Kokkotou, E., Singer, J. P., Kowalczykowski, M., Miller, F. G., Kirsch, I., & Lembo, A. J. (2010). Placebos without deception: A randomized controlled trial in irritable bowel syndrome. PLoS ONE, 5(12), e15591. https://doi.org/10.1371/journal.pone.0015591

Charlesworth, J. E. G., Petkovic, G., Kelley, J. M., Hunter, M., Onakpoya, I., Roberts, N., Miller, F. G., Howick, J., & Kaptchuk, T. J. (2017). Effects of open-label placebo in clinical trials: A systematic review and meta-analysis. Scientific Reports, 7, 2760. https://doi.org/10.1038/s41598-017-03524-5

Lene Vase, Petersen, G. L., Riley, J. L., & Price, D. D. (2023). Open-label placebo treatment: Concepts and relevance for symptom management in serious illness and palliative care. Palliative Medicine, 37(5), 635–645.

Cite as :
Arora, R. D. (2026). Conceptual Engineering (CE7): Acknowledging and addressing questions underlying use of Open-Label Placebos (Version 1) [Report]. Zenodo. https://doi.org/10.5281/zenodo.20745875